|
Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma. |
|
|
No Relationships to Disclose |
|
|
|
|
|
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche/Genentech |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche/Genentech |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche/Genentech |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche Canada |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Roche/Genentech |
Speakers' Bureau - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche/Genentech |
Expert Testimony - Amgen; Bristol-Myers Squibb; MSD; Roche/Genentech |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche/Genentech |
Speakers' Bureau - Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
|
|
Stock and Other Ownership Interests - Genentech |
Patents, Royalties, Other Intellectual Property - Genentech |